Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nls Pharmaceutics Ltd (NLSP)

Nls Pharmaceutics Ltd (NLSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,741
  • Shares Outstanding, K 3,598
  • Annual Sales, $ 0 K
  • Annual Income, $ -1,980 K
  • EBIT $ 0 M
  • EBITDA $ -4 M
  • 60-Month Beta 0.14
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.97
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 01/01/70
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7400 +2.97%
on 10/29/25
2.1500 -64.56%
on 10/02/25
-1.0680 (-58.36%)
since 09/30/25
3-Month
0.7400 +2.97%
on 10/29/25
2.8032 -72.82%
on 08/22/25
-1.2480 (-62.09%)
since 07/30/25
52-Week
0.7400 +2.97%
on 10/29/25
4.7400 -83.92%
on 11/04/24
-3.0980 (-80.26%)
since 10/30/24

Most Recent Stories

More News
NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute

ZURICH and NESS ZIONA, Israel , Nov. 17, 2025 /PRNewswire/ -- NewcelX Ltd . (Nasdaq: NCEL) ("NewcelX" or "the Company"), a clinical-stage biotechnology company developing cell-based and small-molecule...

NCEL : 2.91 (-12.61%)
NLSP : 7.6200 (+2.97%)
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger

Combined Company Re-Named NewcelX Ltd., to Commence Trading on the Nasdaq Capital Market on October 31, 2025 under the Ticker Symbol "NCEL"

NLSPW : 0.0179 (-3.24%)
NLS : 0.8204 (+11.20%)
NCEL : 2.91 (-12.61%)
NLSP : 7.6200 (+2.97%)
NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs

ZURICH , Oct. 30, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP)(Nasdaq: NLSPW) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system and neurodegenerative...

NLSPW : 0.0179 (-3.24%)
NLSP : 7.6200 (+2.97%)
NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger

ZURICH , Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd . (Nasdaq: NLSP) ("NLS" or the "Company"), a biopharmaceutical company focused on developing innovative therapies for central nervous...

NLSP : 7.6200 (+2.97%)
NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem

ZURICH , Oct. 29, 2025 /PRNewswire/ --  NLS Pharmaceutics Ltd.  (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...

NLSPW : 0.0179 (-3.24%)
NLSP : 7.6200 (+2.97%)
NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares

ZURICH and NESS ZIONA, Israel , Oct. 29, 2025 /PRNewswire/ --  NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company") and  Kadimastem Ltd. (TASE: KDST) ("Kadimastem")...

NLSPW : 0.0179 (-3.24%)
KMSTF : 5.0600 (-0.78%)
NLSP : 7.6200 (+2.97%)
NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies

The collaboration will progress under the combined company, NewCelX, upon completion of the anticipated merger

NLSPW : 0.0179 (-3.24%)
NLSP : 7.6200 (+2.97%)
NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025

ZURICH , Oct. 23, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd.  (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on central...

NLSPW : 0.0179 (-3.24%)
NLSP : 7.6200 (+2.97%)
NLS Pharmaceutics Announces Strategic Merger with Kadimastem

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. NLS Pharmaceutics...

NLSP : 7.6200 (+2.97%)
NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting

Vote clears final corporate milestone, paving the way for the closing of the merger and the combined company of NewCelX Ltd., a Nasdaq-listed biotechnology company

NLSP : 7.6200 (+2.97%)

Business Summary

NLS Pharmaceutics Ltd. is a clinical-stage pharmaceutical company. It is focused on the discovery and development of therapies for rare and complex central nervous system disorders. The company's principal product candidate includes Quilience(R). NLS Pharmaceutics Ltd. is based in Switzerland.

See More

Key Turning Points

3rd Resistance Point 0.8780
2nd Resistance Point 0.8540
1st Resistance Point 0.8080
Last Price 7.6200
1st Support Level 0.7380
2nd Support Level 0.7140
3rd Support Level 0.6680

See More

Last Price 7.6200
52-Week High 4.7400
Fibonacci 61.8% 3.2120
Fibonacci 50% 2.7400
Fibonacci 38.2% 2.2680
52-Week Low 0.7400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar